Abstract: Compounds, compositions and methods are provided for treatment of diseases or complications associated therewith, in which a selectin plays a role. More specifically, particular glycomimetics and uses thereof are described. For example, use of particular glycomimetics for treating sickle cell disease or a cancer involving a selectin, or complications associated with either, is described.
Abstract: Provided herein are glycomimetic E-selectin antagonist compounds of formula (I)) and pharmaceutical compositions comprising at least one of the same. The compounds of the present disclosure include trisaccharide domain mimics comprising at least one macrocycle created through the 2nd and 3rd positions on a galactose within the mimic. Methods are also provided comprising using at least one of such compounds and compositions comprising at least one of the same to treat and/or prevent diseases and disorders treatable by inhibiting binding of an E-selectin to an E-selectin ligand.
Type:
Application
Filed:
January 15, 2015
Publication date:
November 17, 2016
Applicant:
GLYCOMIMETICS, INC.
Inventors:
John L. MAGNANI, John M. PETERSON, Mirko ZIERKE, Martin SMIESKO, Beat ERNST
Abstract: Methods for treating and/or preventing mucositis comprising administering to a subject in need thereof an effective amount of at least one compound chosen from E-selectin antagonists, pharmaceutically acceptable salts of E-selectin antagonists, prodrugs of E-selectin antagonists, and pharmaceutically acceptable salts of prodrugs of E-selectin antagonists, and compositions comprising at least one of such compound.
Type:
Application
Filed:
September 29, 2014
Publication date:
August 25, 2016
Applicant:
GLYCOMIMETICS, INC.
Inventors:
John L. MAGNANI, John M. PETERSON, Ingrid G. WINKLER
Abstract: Methods are provided herein for use of E-selectin antagonists for mobilizing cells, such as hematopoietic cells, hematopoietic stem cells and progenitor cells, white blood cells, and malignant cells, and hematopoietic tumor cells from the bone marrow. More specifically, methods are provided for using E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers, and peptides for mobilizing cells from the bone marrow to the peripheral vasculature and tissues.
Abstract: Provided herein are E-selectin antagonist therapeutic agents and improvements thereto and compositions comprising these E-selectin antagonists. Methods are also provided for using these E-selectin antagonist therapeutic agents to treat and/or prevent diseases and disorders treatable by inhibiting binding of an E-selectin to an E-selectin ligand. Also provided herein improvements to E-selectin antagonist glycomimetic compounds that improve the oral bioavailability of the glycomimetic compounds.
Type:
Application
Filed:
October 31, 2013
Publication date:
October 8, 2015
Applicant:
GLYCOMIMETICS, INC.
Inventors:
John L. Magnani, Arun K. Sarkar, John M. Peterson
Abstract: Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation.
Type:
Grant
Filed:
December 21, 2012
Date of Patent:
August 18, 2015
Assignee:
GlycoMimetics, Inc.
Inventors:
John L. Magnani, Arun K. Sarkar, Myung-Gi Baek, Frank E. Anderson, III, Yanhong Li
Abstract: Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation.
Type:
Application
Filed:
December 21, 2012
Publication date:
April 23, 2015
Applicant:
GLYCOMIMETICS, INC.
Inventors:
John L. Magnani, Arun K. Sarkar, Myung-Gi Baek, Frank E. Anderson, III, Yanhong Li
Abstract: Compounds, compositions and methods are provided for inhibiting in vitro and in vivo processes mediated by E-selectin binding. More specifically, particular glycomimetic compounds are described, wherein the compounds are E-selectin antagonists.
Type:
Grant
Filed:
September 12, 2011
Date of Patent:
December 30, 2014
Assignee:
GlycoMimetics, Inc.
Inventors:
Beat Ernst, Céline E. Weckerle, Jonas K. Egger
Abstract: Compounds, compositions and methods are provided for treatment of diseases or complications associated therewith, in which a selectin plays a role. More specifically, particular glycomimetics and uses thereof are described. For example, use of particular glycomimetics for treating sickle cell disease or a cancer involving a selectin, or complications associated with either, is described.
Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).
Type:
Application
Filed:
December 13, 2013
Publication date:
June 26, 2014
Applicant:
GLYCOMIMETICS, INC.
Inventors:
John L. Magnani, John T. Patton, JR., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst
Abstract: Compounds, compositions and methods are provided for use to inhibit infection by human immunodeficiency virus (HIV). More specifically, the present invention relates to glycomimetic compounds that inhibit HIV infection, and uses thereof.
Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).
Type:
Grant
Filed:
June 21, 2011
Date of Patent:
January 21, 2014
Assignee:
Glycomimetics, Inc.
Inventors:
John L. Magnani, John T. Patton, Jr., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst
Abstract: Compounds, compositions and methods are provided for inhibiting in vitro and in vivo processes mediated by E-selectin binding. More specifically, particular glycomimetic compounds are described, wherein the compounds are E-selectin antagonists.
Type:
Application
Filed:
September 12, 2011
Publication date:
December 12, 2013
Applicant:
GLYCOMIMETICS, INC.
Inventors:
Beat Ernst, Céline E. Weckerle, Jonas K. Egger
Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids, which include a portion or analogue thereof) linked to a carbohydrate or glycomimetic.
Type:
Grant
Filed:
April 2, 2010
Date of Patent:
September 10, 2013
Assignee:
Glycomimetics, Inc.
Inventors:
John L. Magnani, John T. Patton, Jr., Leonard M. Williams
Abstract: Methods and medicaments therefor are provided for the treatment of cancers of the blood or a complication therewith in an individual. More specifically, the use of particular glycomimetics for the treatment is described. Methods and medicaments therefor are also provided without regard to cancer type for reducing in an individual the myeloablative bone marrow toxicities of chemotherapy.
Type:
Grant
Filed:
June 10, 2009
Date of Patent:
August 27, 2013
Assignee:
Glycomimetics, Inc.
Inventors:
John L. Magnani, John T. Patton, Jr., Theodore A. G. Smith
Abstract: Compounds, compositions and methods are provided for treating cancer and inflammatory diseases, and for releasing cells such as stem cells (e.g., bone marrow progenitor cells) into circulating blood and enhancing retention of the cells in the blood. More specifically, heterobifunctional compounds that inhibit both E-selectins and CXCR4 chemokine receptors are described.
Abstract: Compounds, compositions and methods are provided for treating cancer and inflammatory diseases, and for releasing cells such as stem cells (e.g., bone marrow progenitor cells) into circulating blood and enhancing retention of the cells in the blood. More specifically, heterobifunctional compounds that inhibit both E-selectins and CXCR4 chemokine receptors are described.
Abstract: Compounds, compositions and methods are provided for treatment of sickle cell disease or a complication associated therewith, or graft versus host disease, in an individual. More specifically, the use of particular glycomimetics for the treatment is described.
Abstract: Compositions and methods are provided related to Pseudomonas bacteria. The compositions and methods may be used for diagnosis and therapy of medical conditions involving infection with Pseudomonas bacteria. Such infections include Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. A compound useful in the present methods may be used in combination with a therapeutic agent or may be linked to a therapeutic agent. Pseudomonas bacteria may be inhibited by blocking colonization, inhibiting virulence factors, arresting growth or killing the bacteria.
Type:
Application
Filed:
August 3, 2012
Publication date:
December 27, 2012
Applicant:
GlycoMimetics, Inc.
Inventors:
John L. Magnani, John T. Patton, JR., Arun K. Sarkar
Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).
Type:
Grant
Filed:
May 30, 2012
Date of Patent:
February 25, 2014
Assignee:
Glycomimetics, Inc.
Inventors:
John L. Magnani, John T. Patton, Jr., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst